Status:
COMPLETED
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Lead Sponsor:
Novartis
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
20-58 years
Phase:
PHASE3
Brief Summary
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to th...
Eligibility Criteria
Inclusion
- Patients should complete the 24 month core study
Exclusion
- Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc.
- Pregnant or nursing women
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
920 Patients enrolled
Trial Details
Trial ID
NCT00662649
Start Date
February 1 2008
End Date
June 1 2011
Last Update
July 12 2012
Active Locations (103)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Chatswood, Australia
2
Novartis Investigative Site
Fitzroy, Australia, 3065
3
Austin Health, Department of Neurology
Heidelberg, Australia
4
Novartis Investigative Site
North Gosford, Australia